EGFR and cancer: Bellevicine et al. [25] demonstrated that IHC analysis using EGFR-mutant-specific antibody could detect 10% of mutated cells from a mixture containing cells harboring either WT or mutant EGFR. In the present study, our dilution series of each mutant EGFR cell line revealed an LOD estimated at between 0.1% and 1% (Fig 3), which meets the sensitivity requirement of CAP/IASLC/AMP guidelines promoting the use of more sensitive tests that can detect mutations in specimens with as few as 20% cancer cells [8].